Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study
Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study
复制标题
DOI：
10.1016/s1386-6346(00)00148-0
复制
发表时间：
2001-07-01
影响因子：
4.2
通讯作者：
Kawasaki, H
中科院分区：
文献类型：
--
作者：
Suou, T;Mitsuda, A;Kawasaki, H
本研究的目的是评估干扰素α（IFN α）治疗是否可以抑制伴有慢性丙型肝炎的小肝癌治愈后的肝内复发。本研究入组了40例患者。他们患有直径小于或等于3 cm的孤立性小HCC，潜在慢性丙型肝炎，年龄小于或等于70岁。在这些患者中，18例在HCC治疗后接受IFN α治疗6个月，22例未接受IFN α治疗的患者用作对照。IFN组6例（33%）患者显示持续应答。局部复发的发生率在干扰素组和非干扰素组中没有差异（6%对9%）。非干扰素组和干扰素组1年、2年、3年、4年和5年的远处复发累积发生率分别为9%和6%、27%和11%、63%和18%、76%和28%、82%和28%，差异有显著性（P < 0.01）。非IFN组中有6例（27%）患者死于HCC进展。而IFN治疗组均存活（P < 0.05）。初步研究表明，小肝癌根治性治疗后的IFN α治疗可以抑制残留肝脏的肝内复发，改善丙型肝炎病毒相关肝癌的预后。(C)2001爱思唯尔科技有限公司。保留所有权利。
The aim of the present study is to evaluate whether interferon alpha (IFN alpha) therapy can inhibit intrahepatic recurrence after the curative treatment of small HCC with underlying chronic hepatitis C. Forty patients were enrolled in this study. They had solitary, small HCC less than or equal to 3 cm in diameter, underlying chronic hepatitis C, and were less than or equal to 70 years old. Of the patients, 18 were treated with IFN alpha for 6 months after the treatment of HCC, and 22 patients who did not receive IFN alpha therapy were used as controls. Six (33%) patients in the IFN group showed sustained response. The incidence of local recurrence was not different in the IFN and non-IFN groups (6 vs. 9%). The cumulative incidences of distant recurrence in the non-IFN and IFN groups were 9 and 6% at 1 year, 27 and 11% at 2 years, 63 and 18% at 3 years, 76 and 28% at 4 years, and 82 and 28% at 5 years; they were significantly different (P < 0.01). Six (27%) patients in the non-IFN group died from the progression of HCC. but all IFN-treated patients were alive (P < 0.05). The pilot study demonstrates that IFN alpha therapy after the curative treatment of small HCC can inhibit intrahepatic recurrence in the remnant liver and improve the prognosis of hepatitis: C virus-related HCC. (C) 2001 Elsevier Science B.V. All rights reserved.